Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07709546

Closed Incision NPWT to Prevent Wound Complications Post-ECMO

Patients undergoing extracorporeal membrane oxygenation (ECMO) are at increased risk of wound complications at the vascular access site after decannulation. These complications may delay recovery and increase healthcare burden. Closed incision negative pressure wound therapy (NPWT) may improve wound healing by reducing fluid accumulation and supporting the incision. This study evaluates whether prophylactic NPWT reduces wound complications compared to standard wound care following ECMO decannulation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Wound healing at the vascular access site is frequently impaired in patients following extracorporeal membrane oxygenation (ECMO). Cannulation-related wound complications (CRWCs), most commonly occurring in the groin, contribute to patient discomfort, delayed recovery, increased nursing workload, and higher healthcare costs.

The aim of this study is to evaluate whether prophylactic negative pressure wound therapy (NPWT) reduces the incidence of CRWCs following ECMO decannulation compared to standard wound care. The primary objective of this randomized controlled trial is to determine whether NPWT is superior to standard wound care with respect to the occurrence of CRWCs within 30 days after decannulation.

This study is designed as a prospective, multi-center, randomized, open-label trial. Adult patients (≥18 years) who have undergone ECMO treatment will be eligible for inclusion.

Following ECMO decannulation, patients in the intervention group will receive prophylactic NPWT applied to the closed groin wound for seven days. Patients in the control group will receive standard wound care using sterile adhesive dressings according to local protocols.

The primary outcome is the incidence of CRWCs within 30 days after ECMO decannulation. Secondary outcomes include the proportion of patients requiring premature discontinuation of NPWT (<7 days) and reasons for discontinuation, length of stay in the intensive care unit and hospital, wound healing status at discharge, and wound-related complications. In addition, patient-reported outcomes will be assessed, including wound-related quality of life (Wound-QoL-14) and general health-related quality of life (EQ-5D-5L) at three months after discharge. Healthcare utilization, including medical consumption and productivity losses, will also be evaluated using validated questionnaires, and total healthcare costs will be assessed up to three months post-discharge.

Patients receiving ECMO are at high risk of complications, including CRWCs, and optimal wound management is essential.

Prophylactic NPWT is already widely used in various surgical settings to support wound healing in high-risk patients. Studies in vascular and other surgical populations have shown that NPWT on groin incisions can significantly reduce surgical site infections and wound-related complications compared to standard dressings. The mechanism of NPWT, including removal of exudate and infectious material, reduction of edema and seroma formation, and stabilization of wound edges, directly targets key factors involved in impaired wound healing after ECMO decannulation.

Participation in this study is associated with minimal additional burden. The intervention is applied as part of routine postoperative care and does not extend beyond the hospital stay. Wound assessments follow standard clinical protocols. Additional data on quality of life and healthcare use will be collected through a digital questionnaire three months after discharge.

Participation is not expected to introduce significant additional risks, while it may offer potential benefits through improved wound healing and reduced complications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is aged 18 years or older
  • Is currently receiving ECMO therapy and is eligible for weaning from the device
  • The patient must have at least one cannula inserted at the groin site
  • (Proxy) informed consent

Exclusion criteria

  • Duration ECMO run < 24 hours
  • Expected death within 24 hours after decannulation
  • Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+)
  • Wound closure is not possible after decannulation.
  • Presence of drain in the wound site
  • Participants who are not proficient in Dutch or English, or whose legal representative is not proficient, if applicable

Treatment and study plan

Prophylactic Closed-Incision Negative Pressure Wound Therapy

Device

Prophylactic closed-incision negative pressure wound therapy (NPWT) is applied immediately following ECMO decannulation to closed groin wounds. The system consists of a sealed dressing connected to a continuous vacuum device set at -125 mmHg and is maintained for seven days without routine dressing changes. This intervention is specifically used to prevent wound complications in high-risk ECMO patients and is applied to one or both groins depending on cannulation.

Other names: NPWT, Closed-Incision NPWT, ciNPWT, Prevena™ system

Standard Wound Dressing

Device

Standard wound dressing is applied to closed groin wounds immediately following ECMO decannulation under sterile conditions. The dressing consists of a conventional sterile adhesive covering without the application of negative pressure or active fluid management. Dressings are changed as clinically indicated according to local standard care protocols.

Other names: Standard Wound Care, Sterile Wound Dressing, Conventional Wound Dressing

Primary outcomes

  1. Cannula-related wound complications (CRWCs)

    Time frame: 30 days after ECMO decannulation

    Cannula-related wound complications (CRWCs) are defined as the occurrence of at least one of the following conditions at the groin cannulation site: hematoma, seroma or fluid collection (with or without exudate leakage), excessive wound exudate, wound dehiscence, fibrinous slough or necrosis, or surgical site infection (SSI) classified according to CDC criteria. In patients with bilateral groin cannulation, the presence of a CRWC at either site is considered as a positive outcome.

Secondary outcomes

  1. Early removal of NPWT

    Time frame: Within 7 days after ECMO decannulation

    Proportion of patients in whom the NPWT system is removed before completion of the intended 7-day treatment period.

  2. Reasons for early NPWT removal

    Time frame: Within 7 days after ECMO decannulation

    Documented reasons for premature discontinuation of NPWT prior to 7 days, including medical, technical, or patient-related factors.

  3. Length of hospital stay

    Time frame: From initial hospital admission until final hospital discharge (variable duration depending on individual hospital stay).

    Hospital length of stay in days, calculated from initial hospital admission to final hospital discharge, including interhospital transfers as part of a single continuous hospital stay.

  4. Length of ICU stay

    Time frame: From ICU admission until ICU discharge, with duration calculated as the number of days between ICU admission and ICU discharge. (variable duration depending on individual ICU stay)

    Duration of ICU stay in days, calculated from ICU admission to ICU discharge.

  5. Medical interventions related to wound complications

    Time frame: Within 30 days after ECMO decannulation

    Occurrence of medical interventions related to cannula-related wound complications, including duration of intensive wound care, use of advanced wound dressings, negative pressure wound therapy (VAC), antibiotic treatment, debridement, surgical interventions (including muscle flap repair), and other wound-related treatments.

  6. Nursing workload and wound care material use

    Time frame: From decannulation until hospital discharge

    Daily nursing time spent on wound care and type and quantity of wound care materials used, recorded until hospital discharge.

  7. Number of participants with a healed groin cannulation site

    Time frame: Assessed at final hospital discharge, occurring at a variable time point depending on the duration of the individual hospital stay.

    A groin cannulation site is considered healed when complete skin closure has been achieved, no wound dressings or dressing changes are required, and no further wound-related interventions are indicated, based on clinical assessment.

  8. EQ-5D-5L index score

    Time frame: At hospital discharge and 3 months after final hospital discharge.

    Health-related quality of life measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Responses are converted into an EQ-5D-5L index value using the applicable value set for economic evaluation and quality-adjusted life year (QALY) calculations. Higher index scores indicate better health-related quality of life. The index score ranges from values below 0 (health states considered worse than death) to 1.0 (full health).

  9. Wound-QoL-14 total score in patients discharged with a wound-related complication

    Time frame: 3 months after final hospital discharge.

    Wound-related quality of life measured using the Wound Quality of Life-14 (Wound-QoL-14) questionnaire in patients discharged from the hospital with a clinically relevant wound complication (CRWC). The Wound-QoL-14 assesses the impact of wound-related symptoms, limitations in daily activities, and psychological burden. Scores are calculated according to the questionnaire scoring manual, with higher scores indicating worse wound-related quality of life.

  10. Healthcare utilization and costs

    Time frame: Up to 3 months after hospital discharge

    Healthcare utilization and associated costs assessed using the iMTA Medical Consumption Questionnaire (iMCQ), including home care involvement, and productivity losses measured using the iMTA Productivity Cost Questionnaire (iPCQ).

Study contacts

Contact information is provided by the study sponsor or research team.

Ineke van de Pol, RN, MSc

CONTACT

[email protected]

+31883206614

Margreet van Rees, RN

CONTACT

[email protected]

0883206612

Sponsors and collaborators

Lead sponsor

St. Antonius Hospital

Other

Collaborators

  • St. Antonius Onderzoeksfonds
  • St. Antonius innovatiefonds

Registry information

Official study title

The Prophylactic Effect of Closed Incision Negative Pressure Therapy on Vascular Entry Site Complications Following ECMO Decannulation

Acronym: PREVENT-ECMO

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jul 16, 2026
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.